Glaucoma and cardiovascular disease. Article announcement in ROJ, issue 3, 2020.

Glaucoma.

Rational treatment of glaucoma in patients with cardiovascular pathology.

Yakubova L.V., Kosakyan S.M., Vasilenkova L.V.

FSBI “National Medical Center for Eye Diseases named after Helmholtz “Ministry of Health of Russia, 105062, Moscow, st. Sadovaya-Chernogryazskaya, 14/19

Summary

Due to the increasing life expectancy of the population worldwide, an increase in the number of patients with glaucoma is expected.

The review presents data on comorbidity and polypharmacy in elderly and senile glaucoma patients.

In addition, these patients are characterized by polypathy: each of them has an average of 6.3 ± 0.6 concomitant somatic diseases. Approximately every fifth patient with glaucoma receives both a systemic and a local beta adrenoreceptor blocking agent (BARBA) at the same time.

The use of local and systemic BARBA in glaucoma patients creates the potential for drug interactions, an increase in the number of side effects, and an earlier onset of the effect of tachyphylaxis. The selectivity of oral and local BARBAs is one of the factors contributing to the prediction of their additive effect.

The data on the advisability of prescribing brimonidine as the first choice drug for patients with glaucoma and ocular hypertension, who were previously prescribed systemic BARBA, are presented.

Key words: beta adrenoreceptor blocking agent, comorbidity, polypathy, polypharmacy, cardiovascular pathology, glaucoma.